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Prostate cancer is a significant global health issue and limitations to current patient 
management pathways often result in over- or under-treatment. New ways to stratify 
patients are urgently needed. We conducted a feasibility study of such novel assessments 
looking for associations between genomic changes and lymphocyte infiltration. An innovative 
workflow utilising an in-house targeted sequencing panel, immune cell profiling using an 
image analysis pipeline, RNA-Seq, and exome sequencing in select cases was tested. 
Gene fusions were profiled by RNA-seq in 27/27 cases and a significantly higher TIL count was 
noted in tumours without a TMPRSS2:ERG fusion compared to those with the fusion (p=0.01). 
Although this finding was not replicated in a larger validation set (n=436) of The Cancer 
Genome Atlas images, there was a trend in the same direction.  Differential expression 
analysis of TIL-High and TIL-Low tumours revealed the enrichment of both innate and 
adaptive immune response pathways. Mutations in mismatch repair genes (MLH1 and MSH6 
mutations in 1/27 cases) were identified.  
We describe a potential immune escape mechanism in TMPRSS2:ERG fusion positive tumours. 
Detailed profiling, as shown here, can provide novel insights into tumour biology. Likely 
differences with findings with other cohorts is related to methods used to define region of 
interest, but this warrants further study in a larger cohort. 
Keywords: inflammation; next generation sequencing; digital image analysis; 




Prostate cancer is a major global health issue, and the second most common cause of cancer 
death in males in the developing world1. Better methods for patient stratification are urgently 
needed.  
Our understanding of the molecular pathology of prostate cancer is evolving fast with 
advances in sequencing methods and bioinformatics.  The Cancer Genome Atlas (TCGA) 
performed detailed molecular analysis on 333 primary prostate carcinomas and 74% of 
tumours fell into one of 7 subtypes defined by specific gene fusions (ERG, ETV1/4, FLI1) or 
mutations (SPOP, FOXA1, IDH1)2.  Recent publications by the International Cancer Genome 
Consortium have identified new cancer genes, routes of progression and drug targets, 
sometimes affected by mutations in non-coding regions of genes including NEAT1 and 
FOXA13.  
There is now greater understanding of the links between morphology and molecular 
alterations (specific morpho-molecular correlations), molecular aberrations and 
inflammation and the therapeutic implications of these associations.  Immunotherapy is a 
treatment option for late stage prostate cancer and in order to optimise response to 
immunotherapy, it is often necessary to target oncogenic driver pathways in combination 
with immunotherapy4. Increasing evidence indicates the clinical utility of inflammatory 
infiltrates in determining cancer prognosis, with a widely accepted role for the immune 
system in controlling cancer growth and progression. In a number of different cancers 
including prostate, colorectal, melanoma and bladder, strong T cell infiltration is associated 
with a favourable clinical outcome5.  
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The literature detailing prostate cancer, progression and inflammation is often conflicting. For 
example, a critical review showed radical prostatectomy cases with higher rates of 
biochemical progression to have higher levels of systemic inflammatory markers. In another 
study, higher grade inflammation was statistically associated with risk of extraprostatic 
extension, positive margins and seminal vesicle invasion6, which is largely contradictory to the 
literature in other tumour types. Issues around accuracy of quantification of inflammatory 
cells, which in many of these studies will have been conducted by pathologist assessment, 
can be addressed with quantitative image analysis. 
Prostate cancer shows a high degree of heterogeneity at histological and genetic levels, which 
poses a significant treatment challenge. As mutations and activation of oncogenic driver 
pathways accumulate with tumour progression, this may promote increases in 
immunosuppressive cells and exhaustion of immune effector cells in the tumour 
microenvironment4.  
A recent study showed 2 of 25 sequenced prostate cancers to be MMR deficient (1 related to 
Lynch syndrome, 1 sporadic) and showed high inflammatory infiltrates and loss of the 2 
relevant MMR proteins on IHC (MSH2 and MSH6)7.  A study describing prostate cancer in 
Lynch syndrome showed tumours to be generally high grade (Gleason Scores 8-10) with 
mutations in MSH2, MLH1 and MSH6 and loss of the respective protein on IHC in 69% of 
tumours8. MSI and dMMR have been reported in prostate cancers to range from 
approximately 1% in primary up to 12% of metastatic cancers9.  
Other associations that have been found between genomics and inflammation include; the 
loss of PTEN and immunosuppression in a dose dependent manner and that the loss or 
mutation of p53 may enhance the immunosuppressive microenvironment4. At fusion level, it 
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has been postulated that TMPRSS2:ERG fusions generate chimeric amino acid sequences that 
are targetable by T cells10. Prediction algorithms have been used to identify potentially 
antigenic epitopes from TMPRSS2:ERG fusions11. 
Here, we aimed to study the relationship between immune cell infiltration and mutations in 




This study involved digital image analysis or next generation sequencing of archival prostate 
cancer samples as depicted in Figure 1. 
Ethics  
The study was undertaken under the Oxford Radcliffe Biobank Research Tissue Bank REC 
approval (reference 09/H0606 5+5) and informed consent was obtained in all cases.  
Cohort 
27 unselected and sequential radical prostatectomy cases stored as FFPE blocks in the 
diagnostic archives of Oxford University Hospitals NHS Foundation Trust. The cases dated 
from 2014-2016 and sequencing was conducted in 2017 and 2018, thus the range of age of 
blocks (samples) was between 1 and 4 years. 18 cases were Gleason Grade Group 2 (Gleason 
Score 7 (3+4)), 7 cases were Grade Group 3 (Gleason Score 7(4+3)) and one of these cases had 
tertiary pattern 5 and 2 cases were Grade Group 5 (Gleason Score 9 (4+5)). 11 cases were 
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prostate confined tumour (stage pT2), 13 showed extraprostatic extension (pT3a) and 2 
showed seminal vesicle invasion (pT3b).  
Staining 
Tissue sections were subject to routine H&E staining, using a Tissue-Tek Prisma Autostainer 
(Sakura, Flemingweg, Netherlands). Immunohistochemistry was performed using a Bond RX 
automatic stainer (Leica Biosystems, Wetzlar, Germany) using the IHC Protocol F program, 
following incubation of sections at 60°C for 10 minutes. This machine performed all steps 
including de-paraffinisation, antigen retrieval and staining, counterstaining and washing using 
Leica Biosystems reagents: Leica Bond Dewax Solution (AR9222), Wash Buffer (AR9590), 
epitope retrieval solution 1 (AR9961), epitope retrieval solution 2 (AR9640), enzyme 1 from 
the enzyme pre-treatment kit (AR9551), and Bond Polymer Detection System (DS9800). 
Epitope retrieval conditions were dependent on the antibody manufacturer’s 
recommendations (Table 1). Antibodies requiring dilution prior to use (anti-FoxP3, anti-PMS2 
and anti-MSH6) were diluted to 1:100 using Bond Primary Antibody Diluent (Leica Biosystems, 
AR9352). For all antibodies, tonsil tissue sections were used as a positive control. Following 
protocol completion, sections were dehydrated with serial 1 minute washes in 70%, 90% and 
twice in 100% ethanol (Sigma Aldrich, St Louis, Missouri, USA -  652261). This was followed by 
2x 5 minute histo-clear II (National Diagnostics, USA HS-202) washes and mounting using 
omnimount (National Diagnostics, HS-110). 
Immunohistochemistry was performed on FFPE tissue with antibodies to CD3, CD4, CD8, 
CD20, Granzyme B, FoxP3, MCK, CK5, MSH2, MSH6, MLH1 and PMS2 on whole mount sections 
and PTEN, AR and ERG on a TMA. Full details of the staining protocols and primary antibodies 
are shown in Table 1. The Bond Polymer Refine Detection kit, which utilises DAB as the 
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chromogen and haematoxylin as the counterstain, was used as the detection system on a 
Leica Bond Immunostainer (Leica Biosystems). Tonsil tissue was used as a positive control for 
all markers.  
Immune Cell Quantification by Digital Image Analysis (DIA) 
Stained sections were scanned at 20x using a NanoZoomer 2.0 digital pathology slide 
scanner (Hamamatsu Photonics, Hamamatsu-City, Japan). Manual visual analysis was 
performed using the Hamamatsu NDP viewer (Hamamatsu Photonics, U12388-01). Digital 
Image Analysis (DIA) was performed using Visiopharm’s Integrator System platform 
(Hoersholm, Denmark), version number 2018.4.3.4480 and image analysis protocols were 
implemented as Analysis Protocol Packages (APP).  
Several APPs were designed to quantify and calculate TIL density on slides stained with CD3, 
CD4, CD8, CD20, FOXP3, GRANB and H&E. The Image analysis process consists of the following 
steps: 
1. Image Alignment/Registration: The Tissuealign module was used to align 3 digitised serial 
sections; two slides stained with tumor markers CK5 and PanCK and another slide stained 
with a cancer biomarker e.g. CD3, CD4, CD20, etc. The alignment was performed both on a 
large scale, and on a finer detailed level, to get the best possible match of the 3 tissue sections. 
The alignments were verified visually. 
2. Detecting Region of Interest (ROI): For invasive tumour detection, a region of interest 
(tumour) detection APP was created. The APP identified panCytokeratin (MCK)+ luminal 
epithelial cells and CK5+ basal cells.  Basal cells are absent in prostate adenocarcinoma glands, 
but present in benign glands (or prostatic intraepithelial neoplasia – PIN). Differential staining 
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was used to define regions of interest (MCK+ CK5+ regions = ‘non tumour’, MCK+ CK5- regions 
= ‘invasive tumour’).  In addition, the tumour region was also additionally divided into invasive 
margin and centre of tumour using an APP built in house using the Erode post-processing 
function of the VIS platform that decreases the tumour region by 120 pixels. The first auxiliary 
APP was run on the slide using threshold classification that identifies the tissue regions. The 
second auxiliary APP was run on the PanCK slide using threshold classification that identifies 
the tumour regions, invasive margin and centre of tumour. The third auxiliary APP was run on 
the CK5 slide using threshold classification that identifies the benign regions. The ROIs were 
then superimposed on the aligned cancer biomarker slide to outline various regions for 
subsequent analysis limited to the inside of the specific regions. The ROI detection APPs 
operates at a low magnification which enables outlining ROIs in a few seconds. We used 50 
patches (0.8mm X 0.8mm) that were generated from 5 representative images to select the 
optimal threshold. Supplementary figure 1 shows the output of the ROI detection pipeline.  
3. Immune Cell Quantification:  HDAB-DAB colour deconvolution band was used to detect 
positively stained cells on CD3, CD4, CD8, CD20, FOXP3 and GRANB slides. H&E-Haematoxylin 
colour deconvolution band was used to detect positively stained lymphocytes on H&E slides. 
To enhance the stained cells, while suppressing the background variation, several pre-
processing steps were included. The colour deconvolution bands were inputted into a 
threshold classifier. Thresholding classification method defines a threshold for a given 
feature, and assigns one class to all pixels with a feature value above or equal to that value, 
and another class for the rest. 




where T is the user-selected threshold (cut-off value), A and B are the labels/classes to which 
the pixel is assigned. 
As post-processing steps; a method for cell separation which is based on shape and size was 
used, cell areas that were too small were removed and finally unbiased counting frames were 
applied to avoid cells that were intersecting with neighbouring tile boundaries and avoid them 
being counted twice (or more). The APPs operate at magnification 10X which enables 
analysing a whole slide image in 5-7 minutes. All immune marker results discussed are density 
as calculated by number of cells detected / area (mm2). 
Quantitative Output Variables and Calculations  
The output variables obtained from the APPs are shown in Table 1. Validation of APPs for 
the quantification of immune infiltrates was achieved by performing a comparison between 
the APP and manual cell counting of equivalent images by a pathologist showed good 
concordance (Supplementary table 1). 
TIL density was also calculated in The Cancer Genome Atlas data set (downloaded from 
portal.gdc.cancer.gov/repository, accessed on 25/08/2019) using the Visiopharm H&E TIL 
APP. As IHC sections are not part of the dataset, ROI was defined by manual pathologist 
annotation on the AIDA platform (https://imageannotation.nds.ox.ac.uk:8443/AIDA/ 
accessed on 24/08/2019) 
Scoring and Morphological Assessments 
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The majority of scoring was done with image analysis as described above. For some of the 
stains (Mib-1, PTEN, PDL-1, AR, ERG), manual pathologist scoring was undertaken as the 
staining pattern was complex and needed some degree of pathologist interpretation.  For 
PTEN and AR, H scoring was undertaken. This is a commonly used scoring system, using the 
following formula [1 × (% cells 1+) + 2 × (% cells 2+) + 3 × (% cells 3+)] with a final score of 0-
300. For PTEN, in addition, guidance available in Ferraldeschi et al. was used, in which an H-
Score of <10 was considered negative and also cases were separately assessed for clonally 
negative areas with any negative areas being regarded overall as negative12. No standard 
definition exists for PTEN positivity or loss by IHC and thus we followed this previously 
described system. In that study, they showed that all cases with a homozygous loss of PTEN 
had loss on IHC, heterozygous loss cases had H Scores of (median) 0-80 (low/absent) and in 
heterozygous loss cases, there was commonly loss of IHC expression. PDL-1 was scored 
according to guidance previously published13 where staining is scored as negative (0), weak 
(1), moderate (2) or strong (3) for specific membrane and cytoplasmic staining of epithelial 
tumor cells. ERG was assessed by a previously described method14 of intensity only scoring. 
Cases are scored from 0-3 by visual assessment and then cases that are scored as 1-3 are 
considered positive (ERG-high) with only cases scored as 0 being considered negative (ERG-
low).  
Tumour budding was defined as previously described in colorectal carcinoma studies as single 
cells or clusters of up to 4 or 5 cells at the invasive tumour front15. Assessment was made 
using standard H&E slides, but if assessment was difficult, this was further facilitated by using 
panCK stains. The border of the tumour was also categorised as being a pushing (or 
expanding) or infiltrating border. A pushing tumour border was described as one with margins 
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which were reasonably well circumscribed, whereas an infiltrative tumour border was 
described as one with dissection of normal tissue with loss of a clear boundary between 
tumour and host tissues15 (Supplementary table 2).   
The presence or absence of an intraductal adenocarcinoma and if present, percentage volume 
was assessed by a pathologist (CV).  If it was unclear from the H&E section, the CK5 stain was 
referred to for clarification.  
DNA Sequencing  
Targeted deep sequencing 
The region of tissue to be used for DNA extraction was determined by pathologist assessment 
of H&E-stained slides and tissue macrodissection was performed. DNA was extracted using 
the High Pure FFPET DNA Isolation kit (Roche, Basel, Switzerland, #06650767001). DNA was 
quantitated using the Qubit dsDNA HS Assay Kit (ThermoFisher Scientific, Massachussetts, 
USA #Q32854) and concentration ranged between 2.3 - 73.5 ng/ul. 50 ng of template DNA 
was used for all samples except one (in which the concentration was lower than 2.5 ng/ul). 
DNA SmMIP sequencing was performed as previously described16. Briefly, single-molecule 
Molecular Inversion Probes (smMIPs) were designed using MIPgen17 and were synthesised by 
Integrated DNA Technologies, Coralville, Iowa, USA. Initially, a capture reaction was 
performed whereby smMIPs anneal to target sequences (50 ng of template DNA), and gap 
filling occurs using the intervening target DNA as a template. Exonuclease treatment is then 
used to remove all linear DNA, leaving circularised smMIPs. PCR using internal primer sites 
amplification of the probes, and sequencing is followed by consensus generation for the 
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genes of interest. Sequencing was performed at a depth of 2000X, to give an effective depth 
>150X after de-duplication. Depth of coverage per probe is shown in Supplementary figure 2. 
The MIP sequencing panel consisted of 3189 MIPs, covering coding exons or hotspots in 23 
genes (AR, ARID1A, CDK12, CHD1, CTNNB1, FOXA1, IDH1, KDM6A, MED12, MLH1, MSH2, 
MSH6, NCOR1, NCOR2, NKX3-1, PIK3CA, PIK3CB, PIK3R1, PTEN, RB1, SPOP, TP53, ZFHX3) and 
spanning ~78 kbp on both strands with an approximate coverage of ~95%.  Genes were 
selected based on a literature review, which included commonly reported prostate cancer 
driver genes18 PIK3CA and TP53 are potential targets of investigational drugs, CTNNB1, IDH1, 
NCOR1, NCOR2 and PIK3R1 are potential targets being investigated chemically3.   
Whole exome sequencing 
Whole exome sequencing was performed in selected samples using the TruSeq DNA Exome 
kit (Illumina, San Diego, California, USA,  #20020614) with the following modifications: A total 
of 100-300ng DNA was used for the library prep, depending on sample quality, pre-
enrichment amplification was done for 12 cycles, and 500ng amplified DNA was taken forward 
for enrichment. Samples were multiplexed and run on a NextSeq 500 sequencer (Illumina) as 
paired-end at 75bp read length, at a minimum average read depth of 70X for tumour samples 
and 35X for matched normal (after filtering PCR duplicates). 
Variant calling 
Targeted sequencing 
For targeted deep sequencing, samples were first deduplicated based on the unique 
molecular index sequence. Somatic variants (SNVs and indels)  were called using Lofreq*19. 
C>T and G>A mutations occurring only on one strand of the template, with a wild-type allele 
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on the complementary strand were considered to be formalin-fixation or PCR artefacts, and 
hence excluded from the list of true mutations. 
Exome sequencing 
For whole exome sequencing, somatic variant calling was performed according to the GATK 
(v4.0.6.0)20 Best Practices workflow and further filtered using custom filters (tlod > 10, SOR < 
2). Briefly, this involved filtering of PCR duplicates, recalibration of base quality, and somatic 
mutation calling with matched normals using Mutect221. 
In both the above analyses, variants were annotated using the Variant Effects Predictor 
(v91.3) (VEP)22. 
RNA Sequencing and analysis 
RNA was extracted from pathologist-marked unstained formalin-fixed paraffin embedded 
radical prostatectomy sections as for DNA, using the High Pure FFPET RNA Isolation kit (Roche, 
Basel, Switzerland #06650775001). RNA was quantitated using the Qubit RNA HS Assay Kit 
(ThermoFisher Scientific, #Q32855). The quality of the RNA was checked using a High 
Sensitivity RNA Screentape (Agilent, Santa Clara, California, USA, #5067- 5579) on a 
Tapestation 2200 (Agilent), with RNA Integrity Numbers ranging from 1 to 4.  
The RNA was depleted of abundant ribosomal transcripts using the NEBNext rRNA Depletion 
Kit (NEB, #E6310L) and libraries were prepared using the NEBNext Ultra II RNA Library Prep 
Kit for Illumina (NEB, #E7770S) according to the manufacturer’s recommendations. The 
resultant libraries were multiplexed and run on a NextSeq 500 sequencer (Illumina) as paired-
end at 75bp read length, at an average of 20 million reads per sample.  
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Reads were demultiplexed, aligned to the reference genome (hg38) using STAR aligner 
(v2.5.0)23 and fusions were called using STAR-Fusion (v1.4.0)24. The called fusions were 
graphically visualised using the Chimeraviz R package (v1.5.6)25. 
For TIL differential expression analysis, median TIL density in the centre of the tumour (H & 
E) was used as a cut-off to stratify patient samples into TIL-High (n = 11) or TIL-Low (n = 12). 
Samples for which TIL counts were not available (n = 4) were excluded. Read counts per 
transcript were generated using Salmon (v0.11.3)26, summarised at gene level using tximport 
(v1.6.0)27 and differential expression analysis was performed using DESeq2 v(1.18.1)28. For 
differential expression analysis based on TMPRSS2:ERG fusion status, samples were stratified 
into fusion-positive (n = 10) or fusion-negative (n = 17) based on STAR-Fusion calls. The rest 
of the differential expression analysis was performed as described above. 
For gene set enrichment analysis, DESeq2-normalised (based on library size) counts were 
provided as input to GSEA (v3.0)29 and tested for enrichment on the KEGG gene sets (from 
the Molecular signatures database MSigDB30) at a nominal p value threshold of 0.05 and FDR 
threshold of 0.25. ‘Signal2Noise’ metric was used for ranking genes. 
HLA typing 
HLA types of all samples were obtained from STAR-aligned RNA-seq data using seq2HLA 
(v2.3)31.  
Neoantigen prediction 
Neoantigens from fusion chimeras were predicted using the INTEGRATE-Neo pipeline 
(v1.2.1)11, again using hg38 as the reference genome, followed by pvacfuse (pvactools v1.0.7). 
Neoantigens from SNVs and short indels were predicted using pvacseq (pvactools v1.0.7)32. 
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In both cases, predictions were made for peptides of 8-11 amino acids length for MHC class I 
and 15 amino acids length for MHC class II. NetMHCpan33 and NetMHCIIpan34 were used as 
the prediction algorithms for MHC class I and class II respectively. 
MSI analysis 
SmMIP targeted sequencing data from matched tumour and normal samples was analysed 
with MSIsensor35. 
Statistical Analysis 
All statistical analyses were performed in R statistical software (v3.4.4). All tests were 
performed at a significance level of α = 0.05, except for FDR < 0.25 for GSEA (according to 





Automated quantification of immune cell infiltrates 
Immune cell infiltration in tumour tissue was quantified on IHC tumour sections using the 
Visiopharm platform (Figure 2). Areas of invasive tumour were identified using MCK and CK5 
staining (see methods for additional details), and then further APPs to quantify immune cells 
were applied. Additional stains and APPs were used to further subclassify the infiltrating 
immune cells into helper (CD4+), cytotoxic (CD8+), regulatory (FOXP3+), activated T 
(Granzyme B+) cells and B (CD20+) cells. In addition, the tumour region was subdivided into 
invasive margin (IM) and the centre of the tumour (CT) based on proximity to benign tissue 
and guidance in previously published literature36, 37. This analysis revealed that the number 
of immune cells within the prostate tumours varied across samples, as well as across immune 
cell subtypes (Figure 3A, B). A moderate to high positive correlation was observed between 
the numbers of different T cell subtypes, particularly among CD3, CD4 and CD8 counts. A high 
negative correlation was seen only between regulatory T cells (FOXP3+) and B (CD20+) cells 
in the invasive margin (Figure 4A). In addition, a high positive correlation was observed 
between TIL counts in IM and CT regions (Pearson's R = 0.86, p < 0.001) (Figure 4B) whereas 
a lower correlation was observed between TIL counts in benign and CT regions (Pearson's R = 
0.41, p = 0.05) (Figure 4C).  
In 22 cases the ROIs were successfully identified by DIA however in 5 cases manual drawing 
was needed due to a complex tumour shape or poor staining on the MCK and CK5 slides.  The 
pipeline was also tested on a TMA as well as the whole slide images used for the main study 
and was able to run successfully on most cores (Supplementary table 3).  
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Identification of gene fusions and correlation with immune cell infiltrates and IHC 
Whole transcriptome RNA sequencing was successfully performed on RNA extracted from 
the 27 FFPE radical prostatectomy samples, to identify gene fusions. In the context of 
prostate cancer, ETS family gene fusions were of particular interest. Fusions involving any 
ETS family gene as the downstream partner were found in 12/27 samples (44%), of which 
10/27 were involving TMPRSS:ERG, 1/27 was TMPRSS2:ETV4 and 1/27 was SLC45A3:ERG. In 
addition, other previously reported gene fusions such as SLC45A2:AMACR and EIF4E3:FOXP1 
were also identified (Table 2). Transcripts and exons involved in TMPRSS2:ERG fusions are 
shown in Supplementary figure 3. 
On IHC scoring, 26 samples (1 excluded in IHC scoring due to no tumour being present), 11 
samples were ERG-high (score > 0) and 25 were ERG-low. 9 samples were fusion positive by 
RNA Seq and 17 were fusion-negative. 2/9 fusion positive samples were ERG-low. 4/17 fusion-
negative samples were ERG-high (Figure 5A). Other fusions were identified with TMPRSS2, 
EU_H had a TMPRSS2:ETV4 fusion. Gene fusions lead to the formation of neopeptides that 
may act as tumour neoantigens. RNA Seq data (above) were used to determine the HLA type 
(MHC class I and II) of the 27 patients. This information combined with the fusion status was 
used to predict the antigenicity of the tumour neopeptides. Table 1 shows the list of fusions 
and the samples for which neoantigens are predicted (binding affinity < 500 nM) 
(Supplementary table 4). The most striking result was that total immune cell counts (identified 
by H & E) in the centre of the tumour were significantly higher (p = 0.01, Wilcoxon test) in the 
TMPRSS2:ERG fusion negative compared to fusion positive samples (Figure 5B). 
We attempted to validate this finding in the TCGA dataset (n=436) using our Visiopharm 
H&E APP, with tumour regions manually marked by a pathologist from H&E images (IHC 
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stains do not form part of this dataset). There was a very small difference between 
TMPRSS2:ERG fusion positive and negative cases, but it was not significant (p-value = 
0.5474) (Supplementary figure 4A). However, importantly the trend was in the same 
direction as our finding of TMPRSS2:ERG fusion and low TILS. Results were similar when 
looking at immune cell density in the centre of the tumour, invasive margin, or all of the 
tumour. 13 samples had been excluded from this analysis due to the low quality of the 
images. Further, a tissue microarray from the CamCap cohort38 (n = 242) was analysed for 
lymphocyte density using our Visiopharm H&E app. There was no significant association 
between lymphocyte density and TMPRSS2:ERG fusion status in this TMA (p = 0.77, Welch’s 
two sample t test) (Supplementary figure 4B). 
In order to determine the TIL signature, the samples were stratified into TIL-High (n = 11) and 
TIL-Low (n = 12) PCa, using the median TIL density in the centre of the tumour (H & E) as the 
cut-off. Samples with tumour area too small to demarcate a non-zero centre were excluded 
(n = 4). Differential expression analysis between these two groups of samples identified 188 
genes that are significantly (adjusted p value < 0.05) up- or down-regulated in TIL PCa (Figure 
5C), of which 84 genes are expressed at least 2-fold higher levels in TIL-High compared to TIL-
Low samples. Salient among these genes are several immunoglobulin proteins (IGLV2-14, 
IGHJ4, IGHG2, IGHJ3, IGHV3-48), granzymes (GZMK, GZMA) and cytokines/cytokine receptors 
(CXCL10, CXCL9, CXCR4). Gene set enrichment analysis of the RNA-seq data revealed that 4 
KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways highly relevant to immune 
responses are significantly enriched (p < 0.05, FDR < 0.25) in TIL-High samples: these are the 
T cell receptor pathway, the B cell receptor pathway, toll-like receptor pathway and genes 
involved in antigen processing and presentation (Figure 5D). SPINK1 (serine protease inhibitor 
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Kazal-type 1) gene is the most significant differentially expressed gene (log2 fold change = 
4.43, adjusted p value < 0.001), and also the gene that is most highly expressed in TIL-High 
samples after SOX9 (Supplementary table 5). ERG gene expression is higher in TIL-Low 
samples and lower in TIL-High samples (log2 fold change = -2.2, adjusted p value = 0.06), but 
this difference falls short of the statistical significance threshold of α = 0.05. Conversely, 
differential expression analysis of TMPRSS2:ERG fusion-positive (n = 10) vs. fusion-negative (n 
= 17) samples identified SPINK1, among other genes, to be highly expressed in fusion-negative 
samples (Supplementary table 6). 
Targeted deep sequencing to identify SNVs and short indels 
In order to further identify neoantigens produced by SNVs and short indels, we chose to 
perform targeted sequencing of 23 prostate cancer driver genes using a single-molecule 
tagged molecular inversion probe panel that was built in-house (6A). This targeted sequencing 
was successful in 18/27 matched tumour:normal samples. A schematic of the panel design is 
show in Figure 6A. Missense single nucleotide variants were identified in 6 genes, and putative 
copy loss was observed in 17 genes in total (Figure 6B). No mutations were observed in the 
targeted genes in 6 patients. Identifying copy number alterations poses a significant problem 
in targeted sequencing, especially in a focused panel such as this. Hence, copy loss of the most 
frequently deleted genes PTEN, CHD1 and RB1 was validated using Taqman real-time PCR 
(Figure 6C). By sequencing and qPCR methods, PTEN was lost in 6/18 cases by sequencing 
loss. However, by IHC, a total of 11/27 cases were found to have a loss of PTEN. Only 2/18 
cases were found to have loss of PTEN both by sequencing as well as IHC.   
No neoantigens were predicted from the 6 missense SNVs identified by targeted sequencing. 
20 
 
Whole exome sequencing in select cases revealed potentially coordinated loss of PIK3R1 
and CHD1 
As very few missense SNVs were identified by targeted sequencing, and no neoantigens were 
predicted from them, it was difficult to draw any conclusions on the relationship between 
immune infiltration and SNVs. Hence, whole exome sequencing was performed in 5 selected 
samples (based on high immune cell infiltrates without explanatory fusions or SNVs in driver 
genes) for a more comprehensive analysis and to identify structural variants, as well as 
validate the findings from the targeted sequencing panel. The missense mutation in SPOP was 
confirmed in sample EU_S, although at a different allele frequency (VAF = 0.38) compared to 
the targeted sequencing (VAF = 0.70). Interestingly, EU_I had the highest number of 
mutations (Figure 7A) as well as the highest total immune cell counts as measured by 
individual markers (Figure 7B). EU_I also had the highest number of neoantigens predicted by 
NetMHCPan and NetMHCIIpan (binding affinity < 500) (Figure 7C). However, no significant 
correlation was found (Pearson’s R = -0.29, p = 0.63) between the number of predicted 
neoantigens and the total number of TILs across the 5 samples (Figure 7D). Copy number 
alterations were identified using GATK4 and are shown as log2 plots of the probes normalised 
to their matched normal (Supplementary figure 5). Interestingly, this revealed that in 3/5 
samples, both PIK3R1 and CHD1 appear to be lost due to structural variations in the long arm 
of chromosome 5. CDH1 (E-cadherin) was lost in 1/5 sample. In addition, MYC was amplified 




Mismatch repair genes mutations 
Somatic missense mutations were observed at an allele frequency of 0.28 and 0.20 by 
targeted deep sequencing in one sample, in MLH1 (I219V involving the DNA mismatch repair 
domain) and MSH6 (S144I) respectively (Figure 8A). To further characterise this, MSH2, MSH6, 
MLH1 and PMS1 were stained in tissue sections using immunohistochemistry. The mutation 
in MSH6 was confirmed by IHC as a loss of staining in most of the tumour region whereas the 
MLH1 mutation was not corroborated by IHC (Figure 8B). No microsatellite instability was 
detected in the markers tested, Bat25 and Bat26 (Figure 8C). Further, testing for 
microsatellite instability in the targeted deep sequencing data identified only 1 somatic site 
out of 27 microsatellite sites for which sequencing data were available (3.7%) indicating that 
there is no microsatellite instability in this sample in spite of the mutations in MMR genes. 
Further, there was no strikingly high immune cell infiltration in this sample. 
Other findings 
There was no relationship between Gleason Grade Group or pathological stage and either 
mutations/copy number changes or fusions or any of the inflammatory parameters.  
Specifically, there was no association between CD3, CD8, CD20, FOXP3, Granzyme B and 
TMPRSS2:ERG fusion as had been observed with TILs in the CT as detected on H&E by image 
analysis.  Although correlation was only seen using the H&E APP in the CT, the APP had been 
validated by manual counting by a pathologist (Supplementary table 2) with close 
concordance (Pearson’s R = 0.99, p<0.0001). 
Supplementary table 3 shows the scoring results of immunohistochemical staining for PDL-1, 
PTEN, AR and ERG.  PDL-1 IHC showed 23/27 cases to have a score of 0, 3 had a score of 1 and 
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1 case had a score of 2. No cases scored 3. The proliferation index with Mib-1 was generally 
low, ranging from 0-8%.  AR staining showed a range of H-Scores from 0-300.   
3 of the cases showed intraductal spread of adenocarcinoma and of 2 of these (EU_15 and 
EU_D), it was only a minor component (5% tumour volume), whereas in the third case, the 
intraductal component was approximately 20% of the tumour volume (EU_07). There were 
no significant relationships between the degree of budding or infiltration at the leading edge 
of the tumour and either sequencing or the inflammatory markers (supplemental table 4).  
None of the cases that showed seminal vesicle invasion showed TMPRSS2:ERG fusion.  
Discussion: 
In this study, we show an inverse association between TMPRSS2:ERG fusion status and TIL 
counts in 27 PCa tumours, and identified a differential gene expression profile in TIL-High vs. 
TIL-Low tumours. We achieved this by utilising a novel workflow which involved the 
integration of digital image analysis techniques to obtain TIL counts, followed by detailed 
gene profiling using RNA and DNA sequencing.  Although the same trend was found when we 
attempted to validate this finding in the TCGA images, it was not statistically significant. Our 
hypothesis is that our smaller dataset of 27 cases had a very detailed image analysis pipeline 
applied where the image analysis was able to define the ROI on a gland-by-gland basis.  This 
is the novel aspect of our pipeline, to use IHC to define a detailed ROI that can unmask 
associations that cannot be identified with a very broad pathologist annotation.  
Other published studies have shown the opposite result from our study with high TILs being 
associated with TMPRSS2:ERG fusion, however, these had the limitations of using IHC on 
TMAs to determine ERG status with manual annotation of ROI39, 40. In our study, RNA Seq 
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was used to specifically identify TMPRSS2:ERG fusion. IHC detects only the expression status 
of ERG which could be because of fusion or transcriptional activation by other means. We 
could find no other studies using RNA Seq and TILs. We also used whole mount sections for 
image analysis quantification and not TMAs, which have inherent problems with sampling 
and automated ROI detection to a gland level rather than pathologist annotation to a 
regional level.  
Our finding of a statistically significant association between low TILs and TMPRSS2:ERG fusion 
remains when the analysis is performed with stratification of samples into TMPRSS2:ERG 
fusions producing chimeric transcripts in the coding exons vs fusion-negative or non-chimeric 
fusions. This raises the intriguing possibility of the down-regulation of immune cell infiltration 
(immune escape) in those samples with TMPRSS2:ERG fusions by an unknown mechanism. A 
recent finding in a mouse model of prostate cancer suggested that the TMPRSS2:ERG fusion 
promotes recruitment of regulatory T cells to the tumour site41. This could be a mechanism 
for immune escape. It has been recently reported that tumours with mutations that bind 
poorly to MHC class II molecules are positively selected42, which may also explain the low 
immune cell counts in TMPRSS2:ERG fusion positive tumours. In any case, the mechanism is 
unlikely to involve neoantigens arising from chimeric proteins, as that would have resulted in 
a higher immune cell infiltration in TMPRSS2:ERG positive tumour. An indirect neoantigen-
independent mechanism, whereby ERG overexpression (driven by the TMPRSS2 promoter) in 
the fusion-positive cases results in suppression of immune response by alteration of cytokine 
production, cannot be ruled out. Indeed, such a mechanism has been proposed to explain 
immune cell infiltration in copy number-driven cancers43. It is acknowledged that a change in 
the number of cases in the cohort could change the value of median cut off used for 
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differential expression analysis. It should also be noted that even though TMPRSS2:ERG status 
was also negatively associated with CD3 lymphocyte density, this did not reach statistical 
significance. 
DIA was used to successfully and accurately distinguish between invasive tumour and non-
tumour, and to quantify inflammatory infiltrates within these regions. Typically, prostate 
cancer invades between and around benign glands, therefore manual annotation of tumour 
regions will often include benign glands. Utilising DIA, increases the accuracy, through 
annotation on an almost gland-by-gland basis.  Furthermore, use of DIA in this manner, 
removes pathologist subjectivity with the inherent problems of inter- and intra-observer 
variability44, 45. One limitation of using CK5 and panCK stains for region of interest detection 
is that both Prostatic Intraepithelial Neoplasia (PIN) and Intraductal Spread of 
Adenocarcinoma retain basal cells like benign glands, but in our study, only 3/27 cases 
showed intraductal spread of adenocarcinoma and usually to a limited degree and therefore 
unlikely to have a major impact on the DIA results.  
This study utilised serial sections with co-registration rather than a multiplex staining 
technique such as the IHC based method published by Linch et al.7 or a more widely used 
immunofluorescence method.  The number of stains that we wished to perform was in excess 
of the number that could be performed with conventional or published IHC or IF methods. In 
addition, we focused here on TILs, but if the amount of tissue were not a limitation, we would 
also have sought to quantify M1 and M2 macrophages and tumour infiltrating neutrophils, 
which have also been found to be important in addition to TILs in tumour progression6.  
Saltz et al. showed that local clustering of TILs may be a more distinctive feature than overall 
TIL infiltrate in some tumour types and this was also the case with prostate cancer46. In this 
25 
 
study, they also demonstrated a brisk band like infiltrate with immune responses forming 
band like boundaries bordering the tumour at its periphery. By contrast, although we 
examined this region in the form of the invasive margin, we did not find this same 
relationship, with inflammatory cells being generally constant across the CT and IM.   
It is previously published that chronic inflammation in benign tissue surrounding PCa is 
common and positively associated with high grade disease, hence we looked at the 
background benign tissue and found a moderate positive correlation between the degree of 
background inflammation and the inflammation in the tumour (total TILs), suggesting that the 
entire prostate is more inflamed when the tumour is more inflamed4. The mechanism for this 
is unclear, and possibly either reflective of a high pre-existing level in the background prostate 
or an elicited response to the tumour. Interestingly, it was observed that when tumours were 
heavily inflamed, the inflammation was often centred around benign glands rather than 
tumour glands (Supplementary figure 6).  In colorectal adenocarcinoma, a body of work 
supports the concept of inflammation at the invasive margin being related to budding and 
EMT15, but we did not find any such associations. 
In tumour progression, FOXP3 expressing T regulatory cells suppress the immune system, 
promoting tumour growth, but by contrast cytotoxic T cells (being associated with a direct 
cytotoxic effect on tumour cells) and T helper cells confer antitumour immunity and are 
associated with better prognosis in patients with cancer47.  Although the role of B 
lymphocytes has been studied less than T cell responses, B cells can play a role in the immune 
system against tumour6.  Despite these previously described associations, we did not find any 
significant results relating to the quantification of subpopulations of TILs.  
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RNA sequencing was successful in all 27 samples. However, targeted DNA sequencing failed 
in 33% of samples, due to poor quality of DNA. This poor quality of DNA is expected due to 
the known deleterious effects of formalin on nucleic acids48. These were unselected 
sequential cases from the diagnostic archives and no special measures had been implemented 
to optimise fixation.  The smMIP panel allowed successful deep sequencing of 23 target genes 
in 18/27 tumour specimens.  The number of SNVs and indels in the targeted genes was low, 
in support of previously published data on prostate cancer, which is generally regarded as a 
mutation poor cancer2. 
Using the TIL counts (H & E) to stratify the samples facilitated the identification of an RNA 
signature in TIL-High samples. While high expression of immune response genes was expected 
in TIL-High samples, it was interesting to note the strong signature of B cell and antigen 
processing signalling pathways, in addition to the T cell signalling pathway, in TIL-High PCa 
samples. This suggests that the anti-tumour immune response in prostate cancer is a 
combination of innate and adaptive immune systems. This evidence underlines the 
importance of both MHC class I and class II molecules in tumour immunity in prostate cancer 
cells. Interestingly, SPINK1 (serine peptidase inhibitor Kazal type 1), a gene known to play an 
important oncogenic role in ETS-fusion negative prostate cancer49, was highly expressed in 
TIL-High samples as well as in TMPRSS2:ERG fusion-negative samples.  
Analysis of CNAs was also performed using the smMIP panel, as previously described50, 51, 
identifying potential deletions of PTEN, CHD1 and PIK3R1. However, this analysis is simplistic, 
and does not account for variation in sequencing depth due to factors such as GC bias, which 
was borne out by low concordance with IHC data (for PTEN) as well as with CNA calls from 
whole exome sequencing data. In contrast, targeted deep sequencing was highly sensitive in 
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identifying SNVs in MLH1 and MSH6 genes at a low minor allele frequency.  There was no 
association between CNA and Gleason Grade Group. It was previously described that more 
aggressive primary tumours tend to show more extensive CNA2. However, our cohort 
comprised mainly Gleason Grade Group 2 cases, which may explain the difference.  
From the whole exome sequencing data, one sample (EU_I) was found to have the highest 
number of predicted neoantigens, which also corresponded to a high number of immune cell 
infiltrates (sum of subtypes). However, across all samples, no overall correlation was observed 
between TILs (by H & E) and the number of putative neoantigens. 
In this study we did not see the association of dMMR and prominent inflammatory infiltrates 
as previously reported7. Targeted DNA sequencing is insufficient to assess total mutational 
burden, which has been postulated to be associated with mutations in MMR genes and 
sensitivity to immune checkpoint inhibitors9. No evidence was found for microsatellite 
instability, which is a consequence of mutations in mismatch repair genes.  
In this study, the relationship between the IHC and the sequencing results was not always an 
exact one. Ong et al. used IHC as an upfront stratifier of intermediate risk prostate cancer 
followed by differential gene expression profiling and their IHC staining of PTEN did not 
correlate with concordant changes in their transcript expression (PTEN loss by IHC 51%)52.  For 
ERG, we had mismatches between TMPRSS2:ERG fusion by RNA Seq and IHC. 2/9 fusion 
positive samples were ERG-low and potential explanations are 1) different regions used for 
IHC vs sequencing, 2) subclone of tumour has TMPRSS2:ERG fusion and IHC may not be 
sensitive enough to detect this, 3) limited tumour available to assess (e.g. EU_O, 
supplemental figure 7). 4/17 fusion-negative samples were ERG-high which can be explained 
by 1) ERG overexpression due to fusion with genes other than TMPRSS2 (e.g. EU_J had a 
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SLC45A3:ERG fusion) 2) other unknown mechanisms of ERG overexpression (EU_H had a 
TMPRSS2:ETV4 fusion). Our rate of concordance between IHC and sequencing was therefore 
78%. ERG status by IHC did not correlate with any of the immune subpopulations or TILs by 
H&E assessment. Rates of correlation between ERG IHC and fusion in other studies include, 
Sung et al.14 (95%) and Gopalan et al.53 (83%).  None, however, has used RNA Seq as the 
platform for determining the TMPRSS2:ERG fusion. In our cohort, ERG fusion was identified 
with genes other than TMPRSS2.  
In conclusion, this study demonstrates the wealth of information that can be obtained from 
pathology archive prostate cancer samples and could be used in discovery, clinical trial or real 
time diagnostic practice. Detailed morpho-molecular associations can be studied by image 
analysis and sequencing, and in this study we report a previously unpublished association 
between TMPRSS2:ERG fusion negative prostate cancer cases and higher levels of TILs. While 
it has been shown that TMPRSS2:ERG fusion status is not a prognostic feature in the clinical 
outcome of prostate cancer in the limited evidence available54, 55, our results suggest that it 
could have important implications in the biology of tumour immune response, and although 
we could not validate this in a larger cohort the explanation is likely due to needing a detailed 
image analysis pipeline on a gland by gland level to discover such associations, which we could 
not utilise in the validation cohort.   
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Figure 1. Workflow used in the study 
Figure 2. Image analysis pipeline to quantify immune cells 
Figure 3. Immune marker profiling using the Visiopharm platform 
A) Absolute immune cell counts in all samples in the centre of the tumour (CT) and B) in the 
invasive margin of the tumour (IM).  
Figure 4. Correlations between immune cell subtypes in different regions of the tumour  
A) Correlogram of immune cell subtypes identified. Blue or red colour scale indicates 
positive or negative correlation respectively, with only those correlations with a p value < 
0.05 (not adjusted for multiple comparisons) being shown. B) Relationship between immune 
cell counts in IM vs. CT (Pearson's R = 0.86, p < 0.001) and C) benign region vs. CT (Pearson's 
R = 0.41, p = 0.05) shown as scatter plots. 
Figure 5. Relationship between TMPRSS2:ERG fusion and immune cell infiltration 
A) ERG overexpression scored by immunostaining largely matches TMPRSS2:ERG fusions 
detected by RNA-seq (p = 0.37, McNemar's Chi square test). B) H & E absolute count in the 
centre of TMPRSS2:ERG fusion negative and positive tumours. (p = 0.01, Wilcoxon test). C) 
Volcano plot showing genes that are significantly differentially expressed between samples 
with high TIL density (High-TIL PCa) versus those with low TIL density (Low-TIL PCa; median 
as cut-off). D) Gene set enrichment analysis showing pathways of interest (in the top 10 
pathways ordered by FDR) enriched between TIL-High PCa vs. TIL-Low PCa. (FDR - False 
Discovery Rate, NES - Normalised Enrichment Score). 
Figure 6. Identification of SNVs and CNAs in FFPE radical prostatectomy samples using a 
PCa-specific panel 
A) Schematic showing the panel design and analysis pipeline. B) Oncoprint summary of 
somatic mutations and copy number alterations in 18 patients. C) Putative copy number 
alterations in PTEN, CHD1 and RB1 were validated using Taqman real-time PCR. 
Figure 7. Exome sequencing of selected cases 
A) SNVs and short indels in 5 samples sequenced by exome capture. B) Immune cell counts 
in the same 5 samples, showing different sub-types quantified on the Visiopharm system. C) 
Number of neoantigens predicted (NetMHCPan/NetMHCIIpan binding affinity < 500 nM) D) 





Figure 8. Mutations in mismatch repair genes 
A) Missense mutations in MLH1 and MSH6 identified by targeted smMIP sequencing. B) H & 
E immunohistochemistry for MLH1 and MSH6, showing loss of staining in MSH6 but not 
MLH1 (dashed line denotes tumour region). Staining pattern in a positive control is also 




Table 1. A summary of antibodies used for immunohistochemistry and specific epitope 
retrieval conditions  
Primary Antibody Type Supplier Cat # Antigen 
Retrieval 
Dilution 
CD3 (LN10) M Leica Biosystems PA0553 20 min ER2 RTU 
CD4 (LB12) M Leica Biosystems PA0427 20 min ER2 RTU 
CD8 (4B11) M Leica Biosystems PA0183 20 min ER2 RTU 
CD20 (L26) M Leica Biosystems PA0200 20 min ER1 RTU 
PDL-1 (E1L3N(R)) M Cell Signaling Technology 13684S 20 min ER2 1/200 
FOXP3 (236A/E7) M Abcam Ab96048 20 min ER1 1/100 
Granzyme B (11F1) M Leica Biosystems PA0291 20 min ER2 RTU 
Cytokeratin 5 
(XM26) 
M Leica Biosystems PA0468 20 min ER2 RTU 
Multicytokeratin 
(AE1/AE3) 
M Leica Biosystems PA0909 10 min Enz 1 RTU 
Androgen Receptor P Abcam ab74272 20 min ER1 1/200 
ERG (EP111) M DAKO M7314 20 min ER1 1/100 
PTEN (Y184) M Abcam ab32199 20 min ER1 1/100 
Mib-1 (ki-67) M DAKO  20 min ER2 1/400 
(M – monoclonal, P – polyclonal) 
CD3 T cell 
CD4 T helper cell 
CD8 Cytotoxic T cell 
CD20 B cell 
PDL-1 PD1 ligand 
FOXP3 T regulatory cell 




Table 2: List of fusions identified by RNA-seq analysis 
Sample Fusions 
EU_0102 TMPRSS2:ERG 











































Supplementary figure legends 
Supplementary figure 1. Tumour Region of Interest (ROI) detection pipeline 
A) The Tissuealign module was used to align 3 digitised serial sections: 2 slides stained with 
tumour markers CK5 and PanCK another slide stained with a cancer or immune biomarker 
(e.g. CD3). B) Regions were labelled as Centre of Tumour (CT) – yellow, Invasive Margin (IM) 
– magenta, benign regions based on CK5 – red, the entire tissue region (to separate it from 
the background) – dark blue, regions that are excluded from the analysis – cyan. C) An 
example of ROI labelling in the tumour microarray. 
Supplementary figure 2. smMIP panel sequencing QC 
The graph shows the percentage of MIPs with the indicated depth of coverage (reads) for 
each sample analysed. NTC = negative control. 
Supplementary figure 3. TMPRSS2:ERG fusion transcripts 
Schematic illustrations of the exons involved in TMPRSS2:ERG fusions discovered in this 
cohort. The vertical lines indicate the exons and the transcripts TMPRSS2 and ERG are 
depicted on the left and right respectively, with their respective ENSEMBL transcript IDs. 
Supplementary figure 4. Association between ERG status and lymphocyte density in the 
TCGA and CamCap datasets 
A) H&E tumour images from the The Cancer Genome Atlas (TCGA) prostate adenocarcinoma 
(PRAD) samples were analysed for lymphocyte density using our pipeline. TMPRSS2:ERG 
fusion status was obtained from the Genomic Data Commons portal. B) Tissue microarrays 
from the CamCap cohort were analysed for ERG status by IHC and lymphocyte density was 
measured using our pipeline. (ns = not significant, p > 0.05, Welch’s two sample t test) 
Supplementary figure 5. Copy number alterations in 5 samples profiled by whole exome 
sequencing 
Copy number alterations are depicted as denoised copy ratios (compared to a panel of 
normals) along with their respective alternate allele frequencies for each sample. 
Supplementary figure 6. Immune cell infiltration centred around the benign glands 
Benign prostate glands were found to have immune cell infiltration around them, as seen by 
Eosin and Hematoxylin staining. 
Supplementary figure 7. Case EU_O with TMPRSS2:ERG fusion by RNA_seq but negative 
for ERG on IHC 
ERG IHC showing the relatively small tumour glands used for assessment (arrow marks 
tumour glands). 

Figure 2. Image analysis pipeline to quantify immune cells. 
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Figure 3. Immune marker profiling using the Visiopharm platform
A) Immune cell densities in all samples in the center of the tumour (CT) 
and B) in the invasive margin of the tumour (IM).





Figure 3. Immune marker profiling using the Visiopharm platform
A) Absolute immune cell counts in all samples in the center of the tumour (CT) and B) in the invasive margin of the 
tumour (IM).
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Figure 4. Correlations between immune cell subtypes in different regions of the tumour
A) Correlogram of immune cell subtypes identified. Blue or red colour scale indicates positive or negative correlation 
respectively, with only those correlations with a p value < 0.05 (not adjusted for multiple comparisons) being shown. 
B) Relationship between immune cell densities in IM vs. CT (Pearson's R = 0.86, p < 0.001) and C) benign region vs.
CT (Pearson's R = 0.41, p = 0.05) shown as scatter plots.
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Supplemental figure 1. Tumour ROI pipeline
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Supplemental figure 6. Case EU O with TMPRSS2:ERG fusion by RNA Seq but negative for ERG on IHC








CD3 121 107 116 
CD20 67 70 66 
CD4 62 61 63 
CD8 49 46 51 
FoxP3 33 34 34 
GranB 28 30 30 
H&E 384 394 390 
 







Circumscribed = 0 
Stage Gleason 
EU_J 0 0 2 3+4 
EU_L 0 0 3a 3+4 
EU_D 1 0 2 3+4 
EU_M 0 0 2 3+4 
EU_H 0 0 2 3+4 
EU_Q 1 1 2 4+3 
EU_B 0 0 3b 4+3 with tertiary pattern 5 
EU_I 0 0 3b 3+4 
EU_S 0 0 2 4+3 
EU_G 0 1 3a 3+4 
EU_R 0 0 3a 3+4 
EU_A 0 1 3a 4+3 
EU_F 0 0 2 3+4 
EU_P 1 1 3b 4+5 
EU_O 1 1 3a 3+4 
EU_N 0 0 3a 4+3 
EU_K 0 0 3a 3+4 
EU_E 0 0 2 3+4 
EU_C 0 0 2 3+4 
EU09 0 0 3a 3+4 
EU07 0 0 3a 4+5 
EU01 0 0 2 3+4 
EU05 0 0 3a 4+3 
EU03 1 1 3a 3+4 
EU15 0 1 3a 4+3 
EU13 0 0 2 3+4 
EU11 0 0 3a 3+4 
 
 
















EU_A 0 1 0 0 200 
EU_C 0 0 0 x x 
EU_K 1 0 0 20 300 
EU07 1 0 0 30 100 
EU_B 0 0 1 0 200 
EU_D 0 1 0 20 200 
EU_J 5 2 0 300 150 
EU01 x x 0 x x 
EU09 0 2 0 30 0 
EU15 5 3 1 100 195 
EU05  1 3 0 0 300 
EU03 1 1 0 40 5 
EUFt 0 0 0 0 100 
EU13 8 0 0 80 5 
EU_N 0 0 0 0 300 
EU_O 5 0 0 50 300 
EU_G 0 0 1 0 200 
EU_I 5 0 0 0 5 
EU_P 5 0 0 0 100 
EU_R 5 2 2 150 200 
EU_H 0 3 0 80 300 
EU_M 5 3 0 40 40 
EU_Q 0 0 0 80 90 
EU_E 0 0 0 80 200 
EU11 1 2 0 0 100 
EU_L 5 3 0 90 70 
EU_S 2 0 0 0 200 
 
Supplementary table 4: Predicted neoantigens 
Neoantigen score for TMPRSS2:ERG fusion peptides for MHC Class I alleles 






EU_03 TMPRSS2>>ERG HLA-B*35:01 10 FPNCPCLLTF 10.5 
EU_05 TMPRSS2>>ERG HLA-B*07:26 10 FPNCPCLLTF 341.7 
EU_09 TMPRSS2>>ERG HLA-B*40:02 9 YETMLTHVL 7.9 
EU_M TMPRSS2>>ERG HLA-A*02:36 10 LLYETMLTHV 23.6 
EU_M TMPRSS2>>ERG HLA-B*07:02 10 FPNCPCLLTF 189.6 
EU_O TMPRSS2>>ERG HLA-B*08:01 10 FPNCIRVHTM 58.8 
 
Neoantigen score for TMPRSS2:ERG fusion peptides for MHC Class II alleles 
sample Gene Name HLA Allele Peptide 
Length 
MT Epitope Seq NetMHCIIpan 
MT Score 
EU_01 TMPRSS2>>ERG HLA-DRB1*07:01 15 TCRLYKQSVSRLLYE 9.68 
EU_09 TMPRSS2>>ERG HLA-
DPA1*01:03/DPB1*60:01 
15 SVSRLLYETMLTHVL 13.03 
EU_M TMPRSS2>>ERG HLA-DRB1*12:01 15 TCRLYKQSVSRLLYE 5.63 
EU_M TMPRSS2>>ERG HLA-DRB1*12:01 15 NCPCLLTFCCHPSGI 162.57 
EU_O TMPRSS2>>ERG HLA-
DPA1*01:03/DPB1*104:01 
15 KYALADFTNRVFPNC 115.3 
 
Supplementary table 5: DE genes in TIL-High vs. TIL-Low 
Top 50 (by fold change) differentially expressed genes between TIL-High (positive log2FoldChange) 
and TIL-Low (negative log2FoldChange) PCa samples. (padj = adjusted p value) 
 
gene_symbol baseMean log2FoldChange pvalue padj 
1 SOX9 4.222591 19.91171 1.51E-11 3.21E-07 
2 SPINK1 189.9429 4.430591 1.07E-08 0.000113 
3 IGHV3-53 5.796331 4.39594 2.30E-05 0.013506 
4 LYPLA2P3 3.237906 -4.13859 5.33E-05 0.021306 
5 MUC13 80.90676 4.1234 1.94E-05 0.012803 
6 IGHJ3 6.071059 3.846454 0.000324 0.044033 
7 RP11-12A20.10 2.153347 -3.8463 0.00013 0.027656 
8 BMP5 45.73508 3.759554 3.89E-05 0.01918 
9 RP1-207H1.2 5.505191 -3.45897 0.000371 0.046371 
10 IGHG2 454.3003 3.431158 0.000182 0.032345 
11 ACTA1 38.08311 -3.35421 8.78E-05 0.026304 
12 IGHV3-48 9.479455 3.307607 0.000117 0.026767 
13 AC009014.3 8.464434 -3.13552 6.98E-07 0.002464 
14 SLCO1B3 47.47918 -3.02279 0.000107 0.026767 
15 IGLV2-14 50.63769 2.922311 8.95E-05 0.026304 
16 LINGO2 3.930789 2.918528 9.80E-05 0.026767 
17 SGO1P1 3.994004 -2.85009 1.76E-05 0.012435 
18 ZDHHC4P1 6.448396 2.773569 2.59E-05 0.014444 
19 NPY4R 28.92077 -2.69979 0.00025 0.03691 
20 GZMK 18.342 2.633104 2.44E-06 0.007083 
21 SELL 68.78225 2.589032 1.17E-05 0.011066 
22 IGHJ4 17.78192 2.551094 0.000255 0.03691 
23 MLC1 8.210756 2.482832 0.000221 0.035361 
24 MTND5P5 5.194503 2.473293 0.000183 0.032345 
25 ATP8A2 90.55514 -2.42375 8.98E-06 0.01003 
26 CXCL10 70.17327 2.397759 9.00E-06 0.01003 
27 BTLA 27.49205 2.372027 0.000155 0.029362 
28 IGF2BP2 110.1526 2.330304 2.87E-06 0.007083 
29 OGDHL 36.4636 -2.32526 5.86E-06 0.01003 
30 MMP9 24.24749 2.304347 9.89E-05 0.026767 
31 CD52 9.614972 2.20557 6.16E-05 0.022286 
32 TRAT1 20.50831 2.199969 0.000102 0.026767 
33 CD1E 7.634753 2.153609 0.000403 0.046747 
34 EPSTI1 76.91579 2.135403 0.000387 0.046747 
35 STAP1 10.86657 2.100702 4.29E-05 0.019726 
36 COL9A2 259.4917 -2.0968 0.000118 0.026767 
37 NKG7 5.958249 2.040286 0.000251 0.03691 
38 LSM1P1 3.043951 -1.99365 0.000225 0.035361 
39 ADGRG5 12.17984 1.981169 0.000178 0.032345 
40 GZMA 6.676635 1.889664 0.0004 0.046747 
41 FCGBP 182.8459 1.861101 0.000155 0.029362 
42 TPO 223.6325 -1.83187 5.10E-05 0.021306 
43 SYT13 67.94423 -1.82028 6.41E-05 0.022286 
44 CXCL9 52.10411 1.819257 0.000409 0.047106 
45 CD86 27.88841 1.81805 0.000359 0.045517 
46 CD48 39.77622 1.761854 0.000191 0.033434 
47 SLAMF1 20.82475 1.754308 0.000137 0.027656 
48 HPGD 304.4284 1.73572 0.000343 0.045154 
49 BCL11B 66.41537 1.708898 0.000203 0.033604 
50 RTP4 10.34162 1.687188 0.000404 0.046747 
 
 
Supplementary table 6: DE genes in TMPRSS2:ERG fusion-positive vs. fusion-negative 
Top 50 (by fold change) differentially expressed genes between TMPRSS2:ERG fusion-positive 
(positive log2FoldChange) and fusion-negative (negative log2FoldChange) PCa samples. (padj = 
adjusted p value) 
 
gene_symbol baseMean log2FoldChange pvalue padj 
1 OR4K12P 31.07744 -8.1252 1.50E-09 8.43E-06 
2 BX072566.1 29.44694 -6.07578 0.000394 0.042153 
3 RP11-162O14.2 7.201725 -5.71551 0.000397 0.042221 
4 GLDC 4.200217 4.529977 3.40E-06 0.001855 
5 CH17-212P11.4 2.319084 -4.3754 0.000319 0.037708 
6 POTEB3 30.49017 -4.37529 1.83E-05 0.005736 
7 RP11-403B2.10 5.042045 -4.30739 0.00013 0.021577 
8 NF1P2 13.72844 -4.29663 4.73E-06 0.002218 
9 RPS3AP54 3.890426 4.129026 1.53E-10 1.37E-06 
10 ATOH1 1.938748 -4.11418 0.00026 0.033349 
11 RP11-983G14.1 7.38755 -4.04284 1.62E-05 0.005227 
12 SLC9C2 4.223327 -3.99862 0.000142 0.023105 
13 RP11-810K23.10 18.3833 -3.91954 7.62E-06 0.002963 
14 RP11-390F4.2 1.861183 3.90548 6.89E-09 2.38E-05 
15 RLN1 70.05678 -3.86248 2.83E-05 0.007508 
16 COL2A1 120.8565 3.840519 1.59E-05 0.005202 
17 MED15P7 8.439892 -3.63639 3.75E-05 0.009187 
18 SPINK1 96.79463 -3.60421 1.69E-06 0.001159 
19 RP11-810K23.9 28.05059 -3.37277 9.82E-05 0.018152 
20 BMP5 48.90497 -3.34981 0.000249 0.032649 
21 TFF3 137.6855 -3.33697 4.79E-06 0.002218 
22 NF1P9 6.038832 -3.32607 0.000512 0.049319 
23 ANKRD34B 36.41605 3.314607 0.000343 0.039405 
24 RP1-207H1.2 4.918794 3.287518 4.51E-05 0.010276 
25 ERG 937.1985 3.233903 1.24E-08 3.07E-05 
26 AC009014.3 9.357759 3.22067 1.82E-10 1.37E-06 
27 RP11-191L9.5 5.660824 3.173773 2.90E-06 0.001769 
28 MUC13 21.02118 -3.01212 7.54E-05 0.014788 
29 CHRM3 324.8776 2.821299 1.50E-08 3.07E-05 
30 TERT 2.373596 2.814404 6.51E-05 0.013224 
31 FTH1P20 20.53278 2.778275 1.24E-05 0.004358 
32 RP11-132A1.6 7.133729 -2.59803 1.57E-05 0.005194 
33 TRPC7 4.071373 2.526416 5.16E-05 0.011185 
34 TDRD1 314.5464 2.503937 3.66E-07 0.000454 
35 AC013410.1 2.173015 2.495773 5.78E-05 0.012074 
36 SERPINA11 5.481057 2.49203 3.64E-05 0.00912 
37 MDFI 43.64216 2.468747 9.51E-08 0.000143 
38 RNF2P1 8.323269 2.442392 3.96E-05 0.009558 
39 SLC29A3 5.871698 -2.4282 0.000424 0.044524 
40 DACT2 65.16056 2.419653 3.62E-06 0.001891 
41 GAPDHP71 4.147833 2.337177 0.0003 0.036221 
42 NPY4R 27.89688 2.318063 0.000236 0.031826 
43 CTB-167G5.7 8.815664 2.310765 0.000383 0.041562 
44 OGDHL 38.29 2.306558 2.06E-07 0.000291 
45 GMNC 9.989964 -2.29828 0.000344 0.039405 
46 C22orf42 8.976664 2.294712 0.000171 0.025663 
47 GZMK 16.74993 -2.24074 0.000198 0.028888 
48 ACTN2 23.99649 -2.20777 0.000434 0.044524 
49 SYT13 70.5699 2.190136 1.24E-08 3.07E-05 
50 C15orf48 38.98175 -2.17798 0.000214 0.030415 
 
Supplementary table 7: Copy number alterations in WES 
Copy number alterations in key prostate cancer driver genes, called from whole exome sequencing 
data of 5 PCa samples 
 Copy loss Copy gain 
EU_B CDH1 MYC 
EU_I CHD1, PIK3R1 MYC 
EU_K   
EU_P CHD1, PIK3R1  
EU_S CHD1, PIK3R1 MAP3K1 
  
 
